Coldstream Capital Management Inc. Raises Holdings in Abbott Laboratories (NYSE:ABT)

Coldstream Capital Management Inc. increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,346 shares of the healthcare product maker’s stock after acquiring an additional 4,063 shares during the period. Coldstream Capital Management Inc.’s holdings in Abbott Laboratories were worth $8,183,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Capital Analysts LLC raised its holdings in Abbott Laboratories by 3.9% during the fourth quarter. Capital Analysts LLC now owns 88,675 shares of the healthcare product maker’s stock worth $10,030,000 after purchasing an additional 3,314 shares during the last quarter. UP Strategic Wealth Investment Advisors LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $268,000. Three Seasons Wealth LLC acquired a new position in Abbott Laboratories during the fourth quarter worth about $1,428,000. Kovitz Investment Group Partners LLC lifted its holdings in shares of Abbott Laboratories by 287.9% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 970,705 shares of the healthcare product maker’s stock valued at $109,797,000 after purchasing an additional 720,451 shares in the last quarter. Finally, Topsail Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $357,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.4 %

Shares of NYSE:ABT opened at $128.90 on Friday. The stock has a 50-day simple moving average of $130.54 and a 200-day simple moving average of $122.41. The stock has a market capitalization of $223.55 billion, a P/E ratio of 16.85, a PEG ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.02. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.83%. Abbott Laboratories’s payout ratio is currently 30.61%.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $133.82, for a total value of $12,199,967.94. Following the sale, the executive vice president now owns 71,928 shares of the company’s stock, valued at $9,625,404.96. This represents a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 116,449 shares of company stock valued at $15,463,316. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of recent research reports. Jefferies Financial Group upped their target price on Abbott Laboratories from $135.00 to $137.00 and gave the company a “hold” rating in a research note on Thursday, April 17th. Stifel Nicolaus increased their price objective on Abbott Laboratories from $135.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, April 17th. Evercore ISI upped their target price on shares of Abbott Laboratories to $136.00 and gave the company a “buy” rating in a report on Thursday, January 2nd. Bank of America lifted their price target on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, Raymond James upped their price objective on shares of Abbott Laboratories from $132.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, April 17th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $142.59.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.